Coya Therapeutics
Tracked across 3 events · 60 articles · First seen Feb 11, 2025 · Last active Jun 02, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Coya Therapeutics is facing multiple class action lawsuits for allegedly misleading investors about the safety of its Duchenne muscular dystrophy gene therapy, Delandistrogene moxeparvovec, after several patient deaths due to acute liver failure. This has led to significant stock price declines and regulatory scrutiny.
Jun 27, 2025 · 44 articles
Business
Impact: Coya Therapeutics is a publicly traded company presenting at the conference, seeking to engage with investors and highlight its advancements.
Apr 02, 2026 · 7 articles
Business
Impact: Dieter Weinand currently serves on the board of Coya Therapeutics, and will reduce his board seats to focus on his role at Evotec.
Apr 07, 2026 · 9 articles
ERGEN INTELLIGENCE
Track Coya Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard